9 results on '"van Meerten, Tom"'
Search Results
2. Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities.
- Author
-
de Boer, Janneke W., Keijzer, Kylie, Pennings, Elise R. A., van Doesum, Jaap A., Spanjaart, Anne M., Jak, Margot, Mutsaers, Pim G. N. J., van Dorp, Suzanne, Vermaat, Joost S. P., van der Poel, Marjolein W. M., van Dijk, Lisanne V., Kersten, Marie José, Niezink, Anne G. H., and van Meerten, Tom
- Subjects
NEUROTOXICOLOGY ,C-reactive protein ,SYNDROMES ,CELLULAR therapy ,FERRITIN ,B cell lymphoma ,MANN Whitney U Test ,CYTOKINE release syndrome ,LACTATE dehydrogenase ,RESEARCH funding ,RECEIVER operating characteristic curves ,LONGITUDINAL method - Abstract
Simple Summary: CAR T-cell therapy became standard of care for patients with relapsed or refractory large B-cell lymphoma. However, their administration can be accompanied by toxicities, such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. It is important to identify patients at risk for these toxicities in order to start an early intervention in high-risk patients and guide outpatient CAR T-cell treatment. As a consequence, several easy-to-use risk scores including the EASIX and its derivatives were developed. However, in the available studies, disparities existed among the used endpoints and cutoff values, hampering the utility of these tools in practice. This study aims to validate these EASIX scores in a population-based cohort. This can be used to select the best predictive model and to further guide optimization of the proposed risk scores. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) can hamper the clinical benefit of CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL). To assess the risk of CRS and ICANS, the endothelial activation and stress index (EASIX), the modified EASIX (m-EASIX), simplified EASIX (s-EASIX), and EASIX with CRP/ferritin (EASIX-F(C)) were proposed. This study validates these scores in a consecutive population-based cohort. Patients with r/r LBCL treated with axicabtagene ciloleucel were included (n = 154). EASIX scores were calculated at baseline, before lymphodepletion (pre-LD) and at CAR T-cell infusion. The EASIX and the s-EASIX at pre-LD were significantly associated with ICANS grade ≥ 2 (both p = 0.04), and the EASIX approached statistical significance at infusion (p = 0.05). However, the predictive performance was moderate, with area under the curves of 0.61–0.62. Validation of the EASIX-FC revealed that patients in the intermediate risk group had an increased risk of ICANS grade ≥ 2 compared to low-risk patients. No significant associations between EASIX scores and CRS/ICANS grade ≥ 3 were found. The (m-/s-) EASIX can be used to assess the risk of ICANS grade ≥ 2 in patients treated with CAR T-cell therapy. However, due to the moderate performance of the scores, further optimization needs to be performed before broad implementation as a clinical tool, directing early intervention and guiding outpatient CAR T-cell treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands.
- Author
-
Spanjaart, Anne M., Pennings, Elise R. A., Mutsaers, Pim G. N. J., van Dorp, Suzanne, Jak, Margot, van Doesum, Jaap A., de Boer, Janneke W., Niezink, Anne G. H., Kos, Milan, Vermaat, Joost S. P., Sijs-Szabo, Aniko, van der Poel, Marjolein W. M., Nijhof, Inger S., Kuipers, Maria T., Chamuleau, Martine E. D., Lugtenburg, Pieternella J., Doorduijn, Jeanette K., Serroukh, Yasmina I. M., Minnema, Monique C., and van Meerten, Tom
- Subjects
RESEARCH ,DISEASE progression ,B cell lymphoma ,CANCER relapse ,TREATMENT effectiveness ,CANCER patients ,SURVIVAL rate ,QUALITY of life ,DESCRIPTIVE statistics ,SURVIVAL analysis (Biometry) ,KAPLAN-Meier estimator ,QUESTIONNAIRES ,RESEARCH funding ,T cells ,PROGRESSION-free survival ,DATA analysis software ,IMMUNOTHERAPY ,OVERALL survival ,PROPORTIONAL hazards models - Abstract
Simple Summary: CAR T-cell therapy has emerged as the new standard of care for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL), but real-world outcomes differ across countries. Additionally, real-world data on health-related quality of life (HR-QoL) are scarce but important, as they reflect the direct experience of patients. In the Netherlands, patients can be referred to the CAR-T tumorboard, a national CAR-T expert panel, who decide whether CAR-T is a feasible treatment option. This multicenter study reports on the favorable outcomes, including the HR-QoL, of axicabtagene ciloleucel (axi-cel) for patients with R/R LBCL after ≥2 lines of systemic therapy in the Netherlands. On the other hand, we show that a substantial proportion of patients are still in need of alternative treatments, including improved CAR-T strategies, as they are unfit for or do not respond to axi-cel. Comparing real-world outcomes between cohorts could help to select best practices and further optimize CAR-T treatment. The real-world results of chimeric antigen receptor T-cell (CAR-T) therapy for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) substantially differ across countries. In the Netherlands, the CAR-T tumorboard facilitates a unique nationwide infrastructure for referral, eligibility assessment and data collection. The aim of this study was to evaluate real-world outcomes of axicabtagene ciloleucel (axi-cel) in the Dutch population, including the thus-far underreported effects on health-related quality of life (HR-QoL). All patients with R/R LBCL after ≥2 lines of systemic therapy referred for axi-cel treatment between May 2020–May 2022 were included (N = 250). Of the 160 apheresed patients, 145 patients received an axi-cel infusion. The main reason for ineligibility was rapidly progressive disease. The outcomes are better or at least comparable to other studies (best overall response rate: 84% (complete response: 66%); 12-month progression-free-survival rate and overall survival rate: 48% and 62%, respectively). The 12-month NRM was 5%, mainly caused by infections. Clinically meaningful improvement in several HR-QoL domains was observed from Month 9 onwards. Expert-directed patient selection can support effective and sustainable application of CAR-T treatment. Matched comparisons between cohorts will help to understand the differences in outcomes across countries and select best practices. Despite the favorable results, for a considerable proportion of patients with R/R LBCL there still is an unmet medical need. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma.
- Author
-
Al-Sarayfi, Diana, Meeuwes, Frederik O., Durmaz, Müjde, Issa, Djamila E., Brouwer, Rolf E., Beeker, Aart, van Rhenen, Anna, Mutsaers, Pim G. N. J., Böhmer, Lara H., van der Poel, Marjolein W. M., te Boome, Liane, van Meerten, Tom, Chamuleau, Martine E. D., Zijlstra, Josée M., Brink, Mirian, and Nijland, Marcel
- Subjects
DIFFUSE large B-cell lymphomas ,B cell lymphoma - Published
- 2022
- Full Text
- View/download PDF
5. Tumour necrosis as assessed with 18F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements.
- Author
-
Kahle, Xaver U., Hovingh, Menno, Noordzij, Walter, Seitz, Annika, Diepstra, Arjan, Visser, Lydia, van den Berg, Anke, van Meerten, Tom, Huls, Gerwin, Boellaard, Ronald, Kwee, Thomas C., and Nijland, Marcel
- Subjects
DIFFUSE large B-cell lymphomas ,B cells ,NECROSIS ,MYC oncogenes ,ANTHROPOMETRY ,B cell lymphoma ,DEOXY sugars ,GLYCOLYSIS ,MULTIVARIATE analysis ,ONCOGENES ,PROGNOSIS ,RADIOPHARMACEUTICALS ,SURVIVAL analysis (Biometry) ,POSITRON emission tomography ,RETROSPECTIVE studies - Abstract
Objectives: MYC gene rearrangements in diffuse large B cell lymphomas (DLBCLs) result in high proliferation rates and are associated with a poor prognosis. Strong proliferation is associated with high metabolic demand and tumour necrosis. The aim of this study was to investigate differences in the presence of necrosis and semiquantitative 18F-FDG PET metrics between DLBCL cases with or without a MYC rearrangement. The prognostic impact of necrosis and semiquantitative 18F-FDG PET parameters was investigated in an explorative survival analysis.Methods: Fluorescence in situ hybridisation analysis for MYC rearrangements, visual assesment, semiquantitative analysis of 18F-FDG PET scans and patient survival analysis were performed in 61 DLBCL patients, treated at a single referral hospital between 2008 and 2015.Results: Of 61 tumours, 21 (34%) had a MYC rearrangement (MYC+). MYC status was neither associated with the presence of necrosis on 18F-FDG PET scans (necrosisPET; p = 1.0) nor associated with the investigated semiquantitative parameters maximum standard uptake value (SUVmax; p = 0.43), single highest SUVmax (p = 0.49), metabolic active tumour volume (MATV; p = 0.68) or total lesion glycolysis (TLG; p = 0.62). A multivariate patient survival analysis of the entire cohort showed necrosisPET as an independent prognostic marker for disease-specific survival (DSS) (HR = 13.9; 95% CI 3.0-65; p = 0.001).Conclusions: MYC rearrangements in DLBCL have no influence on the visual parameter necrosisPET or the semi-quantiative parameters SUVmax, MATV and TLG. Irrespective of MYC rearrangements, necrosisPET is an independent, adverse prognostic factor for DSS.Key Points: • Retrospective analysis indicates that MYC rearrangement is not associated with necrosis on 18 F-FDG PET (necrosis PET ) scans or semiquantitative 18 F-FDG PET parameters. • Necrosis PET is a potential independent adverse prognostic factor for disease-specific survival in patients with DLBCL and is not influenced by the presence of MYC rearrangements. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
6. Novel antibodies against follicular non-Hodgkin’s lymphoma.
- Author
-
van Meerten, Tom and Hagenbeek, Anton
- Subjects
MONOCLONAL antibodies ,LYMPHOMA treatment ,RITUXIMAB ,B cell lymphoma ,GENE expression ,CANCER chemotherapy ,DRUG resistance ,CANCER relapse - Abstract
The anti-CD20 monoclonal antibody rituximab has revolutionized the treatment of patients with follicular B-cell lymphoma. With the combination of chemotherapy and rituximab the overall survival rate has increased with approximately 30%. Unfortunately, there is resistance to rituximab with relapse of the disease in about 60% of the patients during the first five years of treatment and eventually in all patients. To this end, there is a need to develop improved anti-CD20 monoclonal antibodies and antibodies that target other attractive molecules expressed on the follicular lymphoma cell. This review describes the development and clinical achievements so far of next generation anti-CD20 and other antibodies in the treatment of follicular B-cell lymphoma. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
7. WEE1 Inhibition Enhances Anti-Apoptotic Dependency as a Result of Premature Mitotic Entry and DNA Damage.
- Author
-
de Jong, Mathilde Rikje Willemijn, Langendonk, Myra, Reitsma, Bart, Herbers, Pien, Nijland, Marcel, Huls, Gerwin, van den Berg, Anke, Ammatuna, Emanuele, Visser, Lydia, and van Meerten, Tom
- Subjects
ANTINEOPLASTIC agents ,APOPTOSIS ,B cell lymphoma ,CELL cycle ,CELL lines ,CELL physiology ,DNA ,PROTEIN kinase inhibitors ,CELL cycle proteins ,PHARMACODYNAMICS - Abstract
Genomically unstable cancers are dependent on specific cell cycle checkpoints to maintain viability and prevent apoptosis. The cell cycle checkpoint protein WEE1 is highly expressed in genomically unstable cancers, including diffuse large B-cell lymphoma (DLBCL). Although WEE1 inhibition effectively induces apoptosis in cancer cells, the effect of WEE1 inhibition on anti-apoptotic dependency is not well understood. We show that inhibition of WEE1 by AZD1775 induces DNA damage and pre-mitotic entry in DLBCL, thereby enhancing dependency on BCL-2 and/or MCL-1. Combining AZD1775 with anti-apoptotic inhibitors such as venetoclax (BCL-2i) or S63845 (MCL-1i) enhanced sensitivity in a cell-specific manner. In addition, we demonstrate that both G2/M cell cycle arrest and DNA damage induction put a similar stress on DLBCL cells, thereby enhancing anti-apoptotic dependency. Therefore, genotoxic or cell cycle disrupting agents combined with specific anti-apoptotic inhibitors may be very effective in genomic unstable cancers such as DLBCL and therefore warrants further clinical evaluation. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
8. Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma.
- Author
-
Nijland, Marcel, Seitz, Annika, Terpstra, Martijn, van Imhoff, Gustaaf W., Kluin, Philip M, van Meerten, Tom, Atayar, Çiğdem, van Kempen, Léon C., Diepstra, Arjan, Kok, Klaas, and van den Berg, Anke
- Subjects
DOXORUBICIN ,PROTEIN-tyrosine kinase inhibitors ,VINCRISTINE ,RITUXIMAB ,CYCLOPHOSPHAMIDE ,PREDNISOLONE ,BIOPSY ,B cell lymphoma ,CANCER relapse ,CELLULAR signal transduction ,GLYCOPROTEINS ,GENETIC mutation ,ONCOGENES ,RESEARCH ,DRUG development ,DECISION making in clinical medicine ,TREATMENT effectiveness ,SEQUENCE analysis ,GENETICS ,DIAGNOSIS ,THERAPEUTICS - Abstract
Current genomic models in diffuse large B-cell lymphoma (DLBCL) are based on single tumor biopsies, which might underestimate heterogeneity. Data on mutational evolution largely remains unknown. An exploratory study using whole exome sequencing on paired (primary and relapse) formalin fixed paraffin embedded DLBCL biopsies (n = 14) of 6 patients was performed to globally assess the mutational evolution and to identify gene mutations specific for relapse samples from patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. A minority of the mutations detected in the primary sample (median 7.6%, range 4.8–66.2%) could not be detected in the matching relapse sample. Relapsed DLBCL samples showed a mild increase of mutations (median 12.5%, range 9.4–87.6%) as compared to primary tumor biopsies. We identified 264 genes possibly related to therapy resistance, including tyrosine kinases (n = 18), (transmembrane) glycoproteins (n = 73), and genes involved in the JAK-STAT pathway (n = 7). Among the potentially resistance related genes were PIM1, SOCS1, and MYC, which have been reported to convey a risk for treatment failure. In conclusion, we show modest temporal heterogeneity between paired tumor samples with the acquisition of new mutations and identification of genes possibly related to therapy resistance. The mutational evolution could have implications for treatment decisions and development of novel targeted drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
9. Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.
- Author
-
Engelberts, Patrick J., Voorhorst, Marleen, Schuurman, Janine, van Meerten, Tom, Bakker, Joost M., Vink, Tom, Mackus, Wendy J. M., Breij, Esther C. W., Derer, Stefanie, Valerius, Thomas, van de Winkel, Jan G. J., Parren, Paul W. H. I., and Beurskens, Frank J.
- Subjects
- *
IMMUNOGLOBULINS , *B cell receptors , *B cell lymphoma , *LYSIS , *CELL-mediated cytotoxicity , *BLOOD serum analysis , *GENE expression - Abstract
Human IgG1 type I CD20 Abs, such as rituximab and ofatumumab (OFA), efficiently induce complement-dependent cytotoxicity (CDC) of CD20+ B cells by binding of C1 to hexamerized Fc domains. Unexpectedly, we found that type I CD20 Ab F(ab')2 fragments, as well as C1q-binding-deficient IgG mutants, retained an ability to induce CDC, albeit with lower efficiency than for whole or unmodified IgG. Experiments using human serum depleted of specific complement components demonstrated that the observed lytic activity, which we termed "accessory CDC," remained to be dependent on C1 and the classical pathway. We hypothesized that CD20 Ab-induced clustering of the IgM or IgG BCR was involved in accessory CDC. Indeed, accessory CDC was consistently observed in B cell lines expressing an IgM BCR and in some cell lines expressing an IgG BCR, but it was absent in BCR- B cell lines. A direct relationship between BCR expression and accessory CDC was established by transfecting the BCR into CD20+ cells: OFA-F(ab')2 fragments were able to induce CDC in the CD20+BCR+ cell population, but not in the CD20+BCR- population. Importantly, OFA-F(ab')2 fragments were able to induce CDC ex vivo in malignant B cells isolated from patients with mantle cell lymphoma and Waldenström macroglobulinemia. In summary, accessory CDC represents a novel effector mechanism that is dependent on type I CD20 Ab-induced BCR clustering. Accessory CDC may contribute to the excellent capacity of type I CD20 Abs to induce CDC, and thereby to the antitumor activity of such Abs in the clinic. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.